Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03927820 · ClinicalTrials.gov registry record · NA
A Pharmacist-Led Intervention to Increase Inhaler Access and Reduce Hospital Readmissions (PILLAR)
A NA study of Asthma and COPD, sponsored by Vanderbilt University Medical Center.
- Active
- Registry status
- NA
- Development phase
- 914
- Enrollment target
- 1
- Study location
NCT03927820: Active NA study of Asthma and COPD, sponsored by Vanderbilt University Medical Center.
NCT03927820 is a NA study of Asthma and COPD that is active but no longer recruiting, run by Vanderbilt University Medical Center. The registered enrollment target is 914 participants, below the 1,561-participant average among 374 other Asthma trials with a reported enrollment target (41% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03927820, a NA study of Asthma and COPD, is active but no longer recruiting, sponsored by Vanderbilt University Medical Center.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 914 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this study is to assess the impact of pharmacist-led benefits investigations and application of clinical practice guidelines on patient access to inhalers and time to hospital readmission or Emergency Department (ED) visit.
Primary Outcome
Combined time (days) to either hospital readmission or emergency department visit after hospitalization (all outcomes measured at 6 months post-discharge with a 3 month interim analysis)
Interventions
- OTHER Benefits investigation
Study Locations (1)
Tennessee
- Vanderbilt Univeristy Medical Center - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 914 participants |
| Start Date | 2019-09-09 |
| Est. Completion | 2026-06 |
| Phase | NA |
What the registry record for NCT03927820 still lists
NCT03927820 is an interventional study that assigns participants to a tested intervention. The registered 914 participants enrollment target is mid-sized for trials with a published cap, below the 1,561-participant average among 374 other Asthma trials with a reported enrollment target (41% lower).
The record links to 2 conditions, with Asthma appearing as the primary indexed condition, and to 1 intervention - of which Benefits investigation is the first listed.
NCT03927820 reports a single indexed study location in Tennessee.
Frequently Asked Questions
What is clinical trial NCT03927820 about?
NCT03927820 is a clinical study titled "A Pharmacist-Led Intervention to Increase Inhaler Access and Reduce Hospital Readmissions (PILLAR)". The goal of this study is to assess the impact of pharmacist-led benefits investigations and application of clinical practice guidelines on patient access to inhalers and time to hospital readmission or Emergency Department (ED) visit.
What is the current status of trial NCT03927820?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 914 participants. The study started on 2019-09-09. Estimated completion is 2026-06.
What conditions does trial NCT03927820 study?
This clinical trial studies the following conditions: Asthma, COPD.
What interventions are being tested in trial NCT03927820?
The interventions under investigation include: Benefits investigation (OTHER).
Who is sponsoring clinical trial NCT03927820?
This trial is sponsored by Vanderbilt University Medical Center, which has 677 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03927820 being conducted?
This trial has 1 study location across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Asthma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03927820's enrollment target sits among peer trials
914 48th of 374 higher than 327 of 374 other Asthma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Asthma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Automated Inhaler Monitoring for Asthma Medication Usage
RECRUITING · NA
-
Reducing Overuse of Antibiotics With Decision Support
RECRUITING · NA
-
ASTHMAXcel Voice Study
RECRUITING · NA
-
Home Hospital for Suddenly Ill Adults
RECRUITING · NA
-
Asthma and Technology in Emerging African American Adults
RECRUITING · NA
-
BREATHE: An Efficacy-implementation Trial Among Black Adults With Uncontrolled Asthma
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06131840 · 914 participants · Phase 1
A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors
- NCT05739955 · 918 participants · NA
Impact of Enhanced Daily Disinfection on Environmental Contamination in Hospital Rooms
- NCT06216548 · 909 participants · NA
E-PRIME For Children With Medical Complexity
- NCT04589845 · 920 participants · Phase 2
Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI